Review literature on uterine carcinosarcoma

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 3, 2014, Pages 461-468

  Singh, Rajendra ^a  

^a Tarini Cancer Hospital and Research Institute   (India)

Author keywords

Carcinosarcoma; heterologous; homologous; monoclonal; radiation

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOSARCOMA; FEMALE; HUMAN; METASTASIS; PATHOGENESIS; REVIEW; RISK FACTOR; UTERINE CARCINOSARCOMA; UTERUS SARCOMA; DISEASE MANAGEMENT; PROGNOSIS; UTERINE NEOPLASMS;

CARCINOSARCOMA; DISEASE MANAGEMENT; FEMALE; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; RISK FACTORS; UTERINE NEOPLASMS;

EID: 84920846489     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.138197     Document Type: Review

References (81)

1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93:204-8.
2. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19.
3. Olah KS, Dunn JA, Gee H. Leiomyosarcoma have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynecol 1992;99:590-4.
4. Prendiville J, Murphy D, Rennison J, Buckley H, Crowther D. Carcinosarcoma of the ovary treated over a 10 year period at the Christie hospital. Int J Gynecol Cancer 1994;4:200-5.
5. Clement PB, Zubovits JT, Young RH, Scully RE. Malignant mixed tumours of the uterine cervix: A report of 9 cases of a neoplasm with morphology often different from its counterpart in the corpus. Int J Gynecol Pathol 1998;17:211-22.
6. Garamvoelgyi E, Guillou L, Gethard S, Salmeron M, Seematter RJ, Hadjee MH, et al. Primary malignant mixed Mullerian tumour (metaplastic carcinoma) of the female peritoneum. A clinical, pathological, and immunological study of three cases and a review of the literature. Cancer 1994;74:854-63.
7. Chaudhary YS, Illahi F, Moatasim A. Carcinosarcoma uterine unusual histologic presentation. Rawal Med J 2009;34:120-2.
8. Robboy SJ, Mutter GL, Prat J, Bentley RC, Russel P, Anderson MC, et al. Robboy's pathology of the female reproductive tract 2nd edn. china: Churchill Livingstone Elsevier; 2009.p. 443.
9. Gadduci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: A debated critical challenge. Crit Rev Oncol Hematol 2008;65:129-42.
10. Meredith RF, Eisert DR, Kaka Z, Hodgson SE, Johnston GA Jr, Boutselis JG. An excess of uterine sarcomas after pelvic irradiation. Cancer 1986;58:2003-7.
11. Varela-Duran J, Nichomovitz LE, Prem KA, Dehener LP. Postirradiation mixed mullerian tumours of uterus. Cancer 1980;45:1625-31.
12. Zelamanowicz A, Hildesheim A, Hermann ME, Sturgeon SR, Kurman RJ, Barett RJ, et al. Evidence for a common aetiology for endometrial carcinoma and malignant mixed Mullerian tumours. Gynecol Oncol 1998;69:253-7.
13. Amant F, Cadron, Fusol, Breteloot P, de Jonge E, Jacomen G, et al. Endometrial carcinosarcomas have different prognosis and pattern of spread compared to high risk epithelial Cancer. Gynecol Oncol 2005;98:274-80.
14. Wolfson AH, Wolfson DH, Sittler SY, Breton L, Markoe AM, Schwade JG, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994;52:56-62.
15. Schwartz SM, Weiss NS, Daling JR, Gammon MD, Liff JM, Watt J, et al. Exogenous sex hormones use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 1996;77:712-24.
16. Yildirim Y, Inal MM, Sanci M, Yildrim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: A report four cases. Int J Gynecol Cancer 2005;15:1239-42.
17. Arenas M, Rovirosa A, Hernandez V, Ordi J, Jarcano S, Mellado B, et al. Uterine sarcomas in breast cases patients treated with tamoxifen. Int J Gynecol Cancer 2006;16:861-5.
18. Hunag GS, Chiu LG, Gebb JS, Gunter MJ, Sukumavanich P, Goldberg GL, et al. Serum CA125 predict extra uterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007;107:513-7.
19. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen treated breast cancer patients. Finding from the national surgical adjuvant breast and bowel project (NASBP) B-14. J Natl Cancer Inst 1994;86:527-37.
20. Wysowki DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002;346:1832-3.
21. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of literature. Int J Gynecol Cancer 2002;12:496-500.
22. Hubalek M, Ramoni A, Muller-holzner E, Marth C. Malignant mixed mesodermal tumour after tamoxifen therapy for breast cancer. Gynecol Oncol 2004;95:264-6.
23. Giorda G, Franchceschi L, Crivellari D, Magri MD, Veronesi A, Scarbelli C, et al. Determination of tamoxifen and its metabolites in endometrial tissue of long term treated women. Eur J Cancer 2000;36:588-99.
24. Mc Farland J. Dysontogenic and mixed tumours of the urogenital region. Surg Gynecol Obstet 1935;61:42-7.
25. Ober WB. Uterine sarcomas: Histogensis and taxonomy. Ann N Y Acad Sci 1959;75:568-85.
26. Kempson RL, Bari W. Uterine sarcomas. Classification, diagnosis, and prognosis. Hum Pathol 1970;1:331-49.
27. Peters WA 3rd, Kumar NB, Fleming WP, Morley GW. Prognostic features of sarcomas and mixed tumours of the endometrium. Obstet Gynecol 1984;63:550-6.
28. Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, et al. Prognostic factors in uterine carcinosarcoma. A clincopathological study of 25 patients. Cancer 1998;82:512-9.
29. Kumar V, Abbas A, Aster J, Fausto N. Robbins Pathologic Basis of Disease. 7th ed. Philadelphia: W.B. Saunders company; 2005.p. 1088.
30. Fukunaga M, Nomura K, Endo Y, Ushigomes S, Aizawa S. Carcinosarcoma of the uterus with extensive neuroectodermal differentiation. Histopathology 1996;29:565-70.
31. Amant F, Moerman P, Davel GH, Devos R, Vergote I, Lindeque BG, et al. Uterine carcinosarcoma with melanocytic differentiation. Int J Gynecol Pathol 2001;20:186-90.
32. Phillips KA, Scurry JP, Toner G. Alpha-fetoprotein production by a malignant mixed mullerian tumour of the uterus. J Clin Pathol 1996;49:349-51.
33. Shokeir MO, Noel SM, Clement PB. Malignant mullerian mixed tumour of the uterus with a prominent alpha-fetoprotein producing component of yolk sac tumour. Mod Pathol 1996;9:647-51.
34. Major FJ, Blessing JA, Silverberg SG, Marrow CP, Creasman WT, Currie JL, et al. Prognostic factor in early stage uterine sarcoma. A Gynaecologic Oncology Group study. Cancer 1993;71:1702-9.
35. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumours of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317-28.
36. Bocklage T, Lee KR, Belinson JL. Uterine adenosrcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Oncol 1993;44:104-9.
37. Larson B, Silfversward C, Nilsson B, Petterson F. Mixed mullerian tumours of the uterus-prognostic factors: A clinical and histopathologic study of 147 cases. Radiother Oncol 1990;17:123-32.
38. Sreeman JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumours: Further evidence for dominant role of the epithelial component and the conversion theory of histogensis. Am J Surg Pathol 1995;19:666-74.
39. Amant F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Transition of epithelial to mesenchymal differentiation during ovarian carcinosarcoma tumorigensis. Gynecol Oncol 2003;90:372-7.
40. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653-61.
41. Ablen EC, Smit VT, Wessels JW, de Deleeuw WJ, Cornelisse CJ, Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Mullerian tumours. J Pathol 1997;183:424-31.
42. Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, et al. Carcinosarcoma (malignant Mullerian mixed tumours) of the uterus and ovary: A genetic study with special references to histogensis. Int J Gynecol Pathol 2003;22:368-73.
43. Lam KY, Ui Soon K, Cheung A. Collision of endometrioid carcinoma and stromal sarcoma of uterus: A report of two cases. Int J Gynecol Pathol 1999;18:77-81.
44. Mccluggae WG. Uterine carcinosarcomas (malignant mixed Mullerian tumours) are metaplastic carcinosarcomas. Int J Gynecol Cancer 2002;12:687-90.
45. Mccluggage WG. Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinoma. J Clin Pathol 2002;55:321-5.
46. Kuyumcuoglu U, Kale A. Homologous type malignant mixed Mullerian tumour of the uterus presenting as cervical mass. J Chin Med Assoc 2009;72:533-5.
47. EI Husseiny G, AI Bareedy N, Mourad WA, Mohamed G, Shoukri M, Subhi J, et al. Prognostic factors and treatment modalities in uterine sarcoma. J Am Clin Oncol 2002;25:256-60.
48. Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, et al. Serum CA125 predict extra uterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007;107:513-17.
49. Ansink AC, Cross PA, Scorer P, de Lopes AD, Monaghan JM. The hormonal receptor status of uterine carcinosarcomas (MMT) an immunological study. J Clin Pathol 1997;50:328-31.
50. Gagne E, Tetu B, Blondeau L, Raymond PE, Blais R. Morphological prognostic factors of malignant mixed Mullerian tumour of the uterus: A clinicopathologic study of 58 cases. Mod Pathol 1989;2:433-38.
51. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumours of the uterus: Analysis of patterns of failure, prognostic factors and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-96.
52. Afonos JF. Mixed mesodermal tumours of the uterus. West J Med 1974;120:17-26.
53. Manolitsas TP, Wain GV, Williams KE, Friedlander MF, Hacker NF. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumours of the uterus. Cancer 2001;91:1437-43.
54. Molpus KL, Redline-Frazier S, Reed G, Burnett LS, Jones HW 3rd. Postoperative pelvic irradiation in early stage uterine mixed Mullerian tumours. Eur J Gynecol Oncol 1998;19:541-6.
55. Sartori E, Bazzurini L, Gaducci A, Landoni F, Lissoni A, Maggino T, et al. Carcinosarcoma of the uterus a clinicopathologic multicenter CTF study. Gynecol Oncol 1997;67:70-5.
56. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol 2001;27:282-5.
57. Piver MS, Lele SB, Marchetti DL, Emrich LJ. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas. J Surg Oncol 1988;38:233-9.
58. Gaducci A, Fabrini FG, Facchini V, Ducci F, Colosimo S, Dellarciprete T, et al. Surgery and radiotherapy in treatment of early stage uterine sarcomas. Eur J Gynecol Oncol 1989;10:276-80.
59. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:8-13.
60. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole pelvic radiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493-8.
61. Knocke TH, Kucera H, Dolfler D, Pokrajae B, Potter R. Result of postoperative radiotherapy in the treatment of sarcoma of corpus uteri. Cancer 1998;83:1972-79.
62. Smith DC, Macdonald OK, Lee CM, Gaffney DK. Survival impact of lymph node dissection in endometrial adenocarcinoma: A surveillance, epidemiology, and end results analysis J Gynecol Cancer 2008;18:255-61.
63. Salzor OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein ML, Dunne ME, et al. Uterine sarcoma: An analysis of failure with special emphasis on the use of adjuvant radiation therapy. Cancer 1978;42:1161-70.
64. Hornback NB, Omura G, Major FJ. Observation on the uterine sarcomas of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127-30.
65. Menczer J, Levy T, Piura B, Chetrit A, Altaraj M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005;97:166-70.
66. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed Mullerian tumours of the uterine sarcomas. Int J Gynecol Cancer 2006;16:1364-9.
67. Rose PG, Piver MS, Tsukada Y, Lav T. Pattern of metastasis in uterine sarcoma: An autopsy study. Cancer 1989;63:935-8.
68. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yardan E. Phase II trial of cisplatin as first line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic oncology group study. J Clin Oncol 1991;9:1962-6.
69. Homesely HD, Filiaci V, Markman M, Bittermann P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcomas. Gynaecologic Oncology Group Study. J Clin Oncol 2007;25:526-31.
70. Sutton G, Brunetto VL, Kilgore L, Soper JT, Mcgehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynaecologic Oncology Group study. Gynecol Oncol 2000;79:147-53.
71. Curtin JP, Blessing JA, Soper JT, Degeest K. Paclitaxel in the treatment of carcinosarcomas of the uterus: A Gynaecologic oncology group study. Gynecol Oncol 2001;83:268-70.
72. Thigpen JT, Blessing JA, Orr-JW Jr, Disaia PJ. A phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynaecologic oncology group study. Cancer Treat Rep 1986;70:271-74.
73. Gershenson DM, Kavanugh JJ, Copeland LJ, Edward CL, Stringer CA, Wharton JT. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987;5:618-21.
74. Sutton G, Kauderur J, Carson LF, Lentz SS, Whitney W, Gallion H, Gynaecologic oncology group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I and II carcinosarcomas (MMT) of the uterus: A Gynaecologic Oncology Group study. Gynecol Oncol 2005;96:630-4.
75. van Rijswijk RE, Vermorken JB, Reed N, Favalli G, Mendiola C, Zanboni F, et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcomas of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). Eur J Cancer 2003;39:481-7.
76. Currie J, Blessing JA, McGehee R, Soper JT, Berman M, et al. A phase II trial of hdroxyurea, decarbazine and etopside (VP-16) in mixed mesodermal tumours of the uterus: A Gynaecologic oncology group study. Gynecol Oncol 1996;61:94-6.
77. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A Gynaecologic oncology group randomised phase III trial of whole abdominal irradiation (WAI) Vs cisplatin ifosfamide and mesna (CIM) as post surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-85.
78. Miller BE, Blessing JA, Stehman FB, Sahin MS, Yamada SD, Secord AA, et al. A phase II evaluation of weekly gemcitabine and docetaxel for second line treatment of recurrent carcinosarcoma of the uterus: A Gynaecologic oncology group study. Gynaecol Oncol 2010;118;139-44.
79. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ. Response of recurrent uterine high grade malignant mixed mullerian tumour to letrazole. Int J Gynecol Cancer 2005;15:1243-48.
80. Emoto M, Ishiguro M, Iwasaki H, Kikuchi M, Kawarabayashi T. Effect of angiogenesis inhibitor (TNP-470) on the growth, blood flow, and microvessel density in xenografts of human uterine carcinosarcoma in nude mice. Gynecol Oncol 2003;89:88-94.
81. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman J S , Boggess JF, et al. Efficacy and safety of imatinibmesylate and immunohistochemical expression of c-kit and PDGFR-Â in a gynaecologic oncology group phase II trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol 2010;117:248-54.